Form 8-K - Current report:
SEC Accession No. 0001601830-24-000199
Filing Date
2024-11-13
Accepted
2024-11-13 09:22:01
Documents
14
Period of Report
2024-11-13
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rxrx-20241113.htm   iXBRL 8-K 22650
2 EX-99.1 rxrxshareholdervoteresults.htm EX-99.1 17037
  Complete submission text file 0001601830-24-000199.txt   168043

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rxrx-20241113.xsd EX-101.SCH 1788
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rxrx-20241113_lab.xml EX-101.LAB 21629
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rxrx-20241113_pre.xml EX-101.PRE 12512
16 EXTRACTED XBRL INSTANCE DOCUMENT rxrx-20241113_htm.xml XML 2746
Mailing Address 41S RIO GRANDE STREET SALT LAKE CITY UT 84101
Business Address 41S RIO GRANDE STREET SALT LAKE CITY UT 84101 (385) 269-0203
RECURSION PHARMACEUTICALS, INC. (Filer) CIK: 0001601830 (see all company filings)

EIN.: 464099738 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40323 | Film No.: 241451517
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)